The weekly litigation news digest is live. Subscribe now

IP Verse

Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist - EP3107575

The patent EP3107575 was granted to Regeneron Pharmaceuticals on Sep 1, 2021. The application was originally filed on Feb 20, 2015 under application number EP15708991A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3107575

REGENERON PHARMACEUTICALS
Application Number
EP15708991A
Filing Date
Feb 20, 2015
Status
Granted And Under Opposition
Jul 30, 2021
Publication Date
Sep 1, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

NEUEFEINDJun 1, 2022MAIWALDADMISSIBLE
D YOUNGMay 25, 2022D YOUNGADMISSIBLE
DR H ULRICH DORRIESMay 4, 2022DORRIESADMISSIBLE
DR H ULRICH DORRIESMay 4, 2022DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
OPPOSITIONEP14306413
OPPOSITIONNO19983141
OPPOSITIONWO2008054606
OPPOSITIONWO2012047954
OPPOSITIONWO2014031610
OPPOSITIONWO2015127229

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents